Rigosertib Shows Promise in EB-Associated Skin Cancer
METHODOLOGY:
Researchers conducted an open-label, single-arm phase 2 study in Austria and the United States of five patients with advanced, treatment-refractory RDEB-SCC who had failed prior standard of care and were then treated with oral or intravenous (IV) rigosertib.
Participants (median age, 23 years) received either oral rigosertib (560 mg twice daily on days 1-21 of each 28-day cycle for 13 cycles) or IV rigosertib (1800 mg/24 h as a 72-h continuous infusion on days 1-3 of each 14-day cycle for eight cycles, then on days 1-3 of 28-day cycles until 1 year of treatment).
Two patients received IV treatment, two received oral treatment, and one received a combination of both.
The primary outcome was the objective response rate and safety. Quality of life was a secondary outcome.
TAKEAWAY:
Two patients achieved complete a compete response, and two others had partial responses. The fifth patient discontinued treatment early because of unrelated complications.
Rigosertib was generally well tolerated. Most adverse events were urinary-related (cystitis, hematuria) and manageable with dose adjustments or symptomatic treatment.
IN PRACTICE:
'These initial results indicate rigosertib as a promising drug therapy for RDEB-SCC where there is a substantial unmet need and no approved therapies,' the study authors wrote. The study, they noted, was the 'first clinical trial of any experimental cancer therapeutic in this rare and complicated monogenic disease.'
SOURCE:
The study was led by Martin Laimer, Department of Dermatology and Allergology and EB House Austria, University Hospital of the Paracelsus Medical University, Salzburg, Austria, and was published online on May 29 in British Journal of Dermatology .
LIMITATIONS:
Usefulness of imaging techniques in this study was limited, particularly because of the chronic inflammatory response in lesional skin that is inherent to RDEB.
DISCLOSURES:
The study was funded by Debra International through Debra Austria, Debra of America, Cure EB, and Debra UK. Laimer and three other authors reported receiving consulting fees and grants from Onconova Therapeutics, Inc. Two authors declared being employees of Onconova, which provided the study drug.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
3 hours ago
- New York Times
Christie's Debuts Crypto Real Estate Division
One of the United States' largest luxury brokerages is starting a dedicated division to allow buyers to purchase real estate with digital currency. The firm, Christie's International Real Estate, has become the first major brokerage to create a dedicated team of lawyers, analysts and crypto experts to handle transactions in which both the buyer and seller are working exclusively with digital payments and not reliant on any bank, making the move as cryptocurrency continues to zoom its way into mainstream finance. Aaron Kirman, chief executive of a Christie's subset headquartered in Los Angeles, opened the division Thursday after closing a handful of big-ticket deals over the last two years, including the purchase of a $65 million property in Beverly Hills in which the buyers asked the sellers to accept cryptocurrency in lieu of traditional dollars. They did, and Mr. Kirman sensed a shift in the market. 'The trend was obvious — crypto is here to stay,' Mr. Kirman said in an interview. 'It's only going to get bigger over the next few years.' The Trump administration and Washington have rallied behind digital currency. Last week, President Trump signed the landmark Genius Act, which outlines federal rules for stablecoins, a popular form of digital currency designed to maintain a price of $1. The House last week also passed the Clarity Act, which would significantly bolster the crypto industry by shielding it from aggressive regulation. That bill is now headed to the Senate. Want all of The Times? Subscribe.
Yahoo
4 hours ago
- Yahoo
Measles cases in US over 4.5 times higher than all of last year
Measles cases in the United States are continuing to rise after breaking a decades-long record just two weeks ago. There are now 1,319 confirmed measles cases across 39 states, according to data from the Centers for Disease Control and Prevention (CDC) updated Wednesday. This is the highest nationwide measles figure seen since 1992. National cases are more than 4.5 times higher than the entirety of last year, which had an estimated 285 cases reported. MORE: Amid growing Texas outbreak, how contagious is measles? So far, two children and one adult have died from the virus this year, the first deaths from measles in a decade. About one to three of every 1,000 children infected with measles die from respiratory and neurologic complications, according to the CDC. An overwhelming majority of this year's cases -- 92% -- are among those who were unvaccinated or whose vaccination status is unknown, CDC data shows. Measles was declared eliminated from the U.S. in 2000 due to a highly effective vaccination program, according to the CDC Childhood vaccination rates to protect against measles have been declining in recent years, CDC data shows. The rate of kindergarteners receiving state-required vaccinations dropped from 95% in the 2019-2020 school year to less than 93% in the 2023-2024 school year, according to CDC data. A 95% threshold is the ideal level to protect for herd immunity, public health experts note. This leaves about 280,000 U.S. kindergarteners, or 7.3%, without protection from the virus. MORE: Amid growing Texas outbreak, how contagious is measles? A measles vaccine became available in 1963. Prior to that, nearly all children got measles by the time they were 15 years old. It led to an estimated 500 deaths and 48,000 hospitalizations each year before the shot was widely available, according to the CDC. Children in the U.S. are recommended to receive the two-dose measles, mumps, and rubella (MMR) vaccine with the first dose at 12 to 15 months of age and the second between 4 and 6 years old. One dose is 93% effective, and two doses are 97% effective, the CDC says. A booster shot is not typically recommended for adults who already have immunity from the virus through vaccination or prior infection. Solve the daily Crossword
Yahoo
4 hours ago
- Yahoo
EU-US trade deals buoy stocks while Tesla plummets
Stock markets mostly bumped upwards Thursday as hopes grew that the European Union could strike a trade deal with the United States, while Tesla shares nosedived on poor earnings results. Investors have profited in recent weeks from wagers that governments will eventually hammer out pacts with Donald Trump ahead of the US president's looming August 1 deadline to avoid steeper levies. analyst Patrick O'Hare said Trump's Tuesday trade announcement with Japan had raised hopes about further agreements. "There is underlying enthusiasm for more trade deals being struck before the August 1 deadline," O'Hare said. This was boosted further by "optimism surrounding trade talks between the US and EU", said Joshua Mahony, chief market analyst at Rostro trading group. On Wall Street, both the S&P 500 and tech-heavy Nasdaq edged higher in the morning's trading, although the Dow slid lower as investors digested mixed company earnings. Google parent Alphabet was among the early gainers, rising about three percent after reporting a whopping $28.2 billion in second-quarter profits as it touted its artificial intelligence offerings. But Tesla fell around nine percent as CEO Elon Musk warned investors of a rough patch for earnings after the electric car maker reported a 16-percent drop in quarterly profits. A survey of US manufacturers released Thursday showed business confidence in the world's top economy also deteriorated in July for the second month running. "Companies cite ongoing concerns over the impact of government policies, notably in terms of both tariffs and cuts to federal spending," said Chris Williamson, Chief Business Economist at S&P Global Market Intelligence. In Europe, London's FTSE 100 gained 0.9 percent at the close, lifted by a stream of robust earnings, including from consumer goods group Reckitt, mobile phone giant Vodafone and Lloyds bank. Paris fell, dragged down by a drop in luxury stocks and disappointing profits from fossil fuel giant TotalEnergies. Yet most other European stocks markets including Frankfurt rose, as the European Union and Washington appeared close to a deal that would halve a threatened 30-percent levy on EU goods to 15 percent. A European Commission spokesman said Thursday that he believed a trade deal with the US is "within reach". According to multiple diplomats, the deal could waive tariffs on aircraft, lumber, pharmaceutical products and agricultural goods. The bloc, however, is still forging ahead with contingency plans in case talks fail, with member states approving a 93-billion-euro ($109-billion) package of counter-tariffs on US goods. Meanwhile, the European Central Bank left interest rates unchanged, as widely expected. It warned that the economic environment remained "exceptionally uncertain, especially because of trade disputes" as higher US tariffs hang in the balance. The euro dipped a touch following Thursday's rate decision, but it did perk up after ECB President Christine Lagarde said the central bank was monitoring the dollar-euro exchange rate but had no target. The euro has surged almost 14 percent against the dollar since the start of the year, boosted by investors dumping US assets in the face of Trump's impetuous policymaking and attacks on the US Federal Reserve. The euro's appreciation helps contain inflation but could harm European exports and thus slow already sluggish economic growth. In Asia, stocks advanced with Tokyo adding more than one percent, building on a more than three percent surge Wednesday on the back of the Japan-US trade deal. Hong Kong and Shanghai also rose. - Key figures at around 1530 GMT - New York - Dow: DOWN 0.4 percent at 44,851,07 points New York - S&P 500: UP 0.3 percent at 6,375.34 New York - Nasdaq Composite: UP 0.3 percent at 21,075.70 London - FTSE 100: UP 0.9 percent at 9,138.37 (close) Paris - CAC 40: DOWN 0.4 percent at 7,818.28 (close) Frankfurt - DAX: UP 0.2 percent at 24,295.93 (close) Tokyo - Nikkei 225: UP 1.6 percent at 41,826.34 (close) Hong Kong - Hang Seng Index: UP 0.5 percent at 25,667.18 (close) Shanghai - Composite: UP 0.7 percent at 3,605.73 (close) Dollar/yen: UP at 146.79 yen from 146.47 yen on Wednesday Euro/dollar: DOWN at $1.1774 from $1.1777 Pound/dollar: DOWN at $1.3537 from $1.3579 Euro/pound: UP at 86.98 pence from 86.68 pence West Texas Intermediate: UP 1.3 percent at $66.09 per barrel Brent North Sea Crude: UP 1.1 percent at $69.26 per barrel burs-sbk/rl Sign in to access your portfolio
